Yoo N C, Chung H C, Chung H C, Park J O, Rha S Y, Kim J H, Roh J K, Min J S, Kim B S, Noh S H
Yonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Yonsei Med J. 1998 Feb;39(1):27-36. doi: 10.3349/ymj.1998.39.1.27.
Soluble forms of ICAM-1 (sICAM-1) and VCAM-1 (sVCAM-1) have been reported from the supernatant of cytokine-activated endothelial cells, cancer cells and from sera of cancer patients. We measured sICAM-1 and sVCAM-1 from the serum of 20 healthy volunteers and 142 gastric cancer patients by ELISA assay. Ninety-five patients were operable and 47 patients were in-operable at the time of this study. Particularly in the 28 operable patients, we sampled both portal and peripheral blood simultaneously and measured the levels of the soluble forms of cell adhesion molecules (sCAMs). The sCAMs level and sero-positivity rate increased with cancer progression in order of the healthy controls, operable patients, and inoperable patients. In in-operable cancer, the sICAM-1 level increased more with liver metastasis. sICAM-1 and sVCAM-1 did not correlate with each other in either portal or peripheral blood. A total of 58.3% of patients with liver metastasis and 22.9% of patients without liver metastasis showed synchronous expression of both sCAMs (p = 0.03). Synchronous sero-positivity of sCAMs and alpha FP was higher with liver metastasis (p = 0.01). The median overall survival duration which co-expressed both sCAMs was 9 months. This showed a significant difference compared with the sICAMs non-expressing group, where the median survival was not reached until 24 months follow-up (p = 0.002). The synchronous expression of sCAMs was an independent risk factor in gastric cancer patients. We raise the possibility that synchronous sICAM-1 and sVCAM-1 elevation may be a useful monitor to determine tumor burden in gastric cancer.
细胞间黏附分子-1（ICAM-1）和血管细胞黏附分子-1（VCAM-1）的可溶性形式已在细胞因子激活的内皮细胞、癌细胞的上清液以及癌症患者的血清中被报道。我们通过酶联免疫吸附测定法（ELISA）检测了20名健康志愿者和142名胃癌患者血清中的sICAM-1和sVCAM-1。在本研究时，95名患者可进行手术，47名患者无法进行手术。特别是在28名可手术患者中，我们同时采集了门静脉血和外周血，并测量了细胞黏附分子可溶性形式（sCAMs）的水平。sCAMs水平和血清阳性率随着癌症进展而升高，顺序为健康对照组、可手术患者和不可手术患者。在不可手术的癌症中，sICAM-1水平随着肝转移而升高得更多。sICAM-1和sVCAM-1在门静脉血或外周血中均不相互关联。共有58.3%的肝转移患者和22.9%的无肝转移患者显示两种sCAMs同步表达（p = 0.03）。sCAMs与甲胎蛋白（alpha FP）的同步血清阳性在肝转移患者中更高（p = 0.01）。同时表达两种sCAMs的患者的中位总生存期为9个月。这与未表达sICAMs的组相比有显著差异），该组直到24个月随访时中位生存期仍未达到（p = 0.002）。sCAMs的同步表达是胃癌患者的一个独立危险因素。我们提出同步的sICAM-1和sVCAM-1升高可能是确定胃癌肿瘤负荷的有用监测指标的可能性。
